A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,108

Participants

Timeline

Start Date

Not specified

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Overactive Bladder
Interventions
DRUG

YM178

Trial Locations (84)

Unknown

3 Sites, Antwerp

2 Sites, Brussels

Ghent

Leuven

Liège

Brno

Mělník

Ostrava

3 Sites, Prague

Ústí nad Labem

Zlín

Holbæk

Kolding

Roskilde

2 Sites, Nantes

2 Sites, Paris

Bad Ems

Bamberg

Bautzen

Berlin

Dresden

Frankfurt

Hagenow

Halle

Hamburg

Koblenz

Leipzig

München

Radebeul

Trier

Uetersen

3 Sites, Athens

Pátrai

Miskolc

Nyíregyháza

Pécs

Sopron

Szeged

Tatabánya

Catanzaro

Milan

Modena

Padua

Roma

Sassari

Torino

Udine

Varese

Amsterdam

Apeldoorn

Arnhem

Eindhoven

Enschede

Maastricht

Bergen

Oslo

Tønsberg

Bialystok

Katowice

Kielce

Lublin

3 Sites, Warsaw

3 Sites, Wroclaw

7 Sites, Moscow

3 Sites, Saint Petersburg

2 Sites, Barcelona

Bilbao

2 Sites, Madrid

Manacor

Miranda de Ebro

San Juan de Alica

Seville

Vigo

Gothenburg

2 Sites, Stockholm

Birmingham

Blackburn

Chichester

Croydon

London

Reading

Sheffield

Southampton

Swansea

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Europe B.V.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00337090 - A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) | Biotech Hunter | Biotech Hunter